Wessam Elsawy: Pharmacology_Exam_1_6-11-25_clean
Back to ExamScore
86.0%
Rank
15
Points
43.0
Status
PASS
Performance Comparison
Performance by Category
Question Answers
| Q# | Your Answer | Correct | Points | Action |
|---|---|---|---|---|
| 1 | D. Na+-CL– symporter | Yes | 1.0/1.0 | |
| 2 | A. Hypertensive emergency | Yes | 1.0/1.0 | |
| 3 | E. Begin a calcium channel blocker for initial treatment | No (A. Counsel on lifestyle changes and follow up in 3 months) | 0.0/1.0 | |
| 4 | D. Lisinopril | Yes | 1.0/1.0 | |
| 5 | B. Hydrochlorothiazide | Yes | 1.0/1.0 | |
| 6 | A. Aliskiren | No (D. None of these drugs) | 0.0/1.0 | |
| 7 | A. Bradykinin | Yes | 1.0/1.0 | |
| 8 | E. E | Yes | 1.0/1.0 | |
| 9 | A. Educate the patient on hypertension risks and initiate a losartan 25 mg daily | Yes | 1.0/1.0 | |
| 10 | B. Discontinue ACE inhibitor and switch to labetalol or methyldopa | Yes | 1.0/1.0 | |
| 11 | A. Venlafaxine | Yes | 1.0/1.0 | |
| 12 | B. Amlodipine 10 mg | Yes | 1.0/1.0 | |
| 13 | A. Patients with heart failure with reduced ejection fraction and persistent symptoms | Yes | 1.0/1.0 | |
| 14 | E. Angiotensin-converting enzyme inhibitors that inhibit renin-angiotensin system | Yes | 1.0/1.0 | |
| 15 | C. Combination can cause severe hypotension and is contraindicated | Yes | 1.0/1.0 | |
| 16 | C. Release nitric oxide, increasing cGMP to relax vascular smooth muscle | Yes | 1.0/1.0 | |
| 17 | A. Improves insulin sensitivity and reverses diabetic nephropathy progression | No (B. Reduces cardiovascular death and heart failure hospitalizations) | 0.0/1.0 | |
| 18 | B. Administer intravenous loop diuretic therapy | Yes | 1.0/1.0 | |
| 19 | C. Phosphodiesterase-3 inhibition to increase intracellular cAMP | Yes | 1.0/1.0 | |
| 20 | D. Initiate chlorthalidone therapy | Yes | 1.0/1.0 | |
| 21 | C. Accumulation of cyanide metabolites | Yes | 1.0/1.0 | |
| 22 | B. Location G where the drug inhibits Na⁺-K⁺-2Cl⁻ cotransport | Yes | 1.0/1.0 | |
| 23 | A. Duloxetine | No (D. Pioglitazone) | 0.0/1.0 | |
| 24 | D. Reduce afterload | Yes | 1.0/1.0 | |
| 25 | A. Carvedilol | Yes | 1.0/1.0 | |
| 26 | C. Lisinopril impairing renal perfusion and increasing digoxin toxicity | No (B. Hydrochlorothiazide causing hypokalemia and increasing digoxin toxicity) | 0.0/1.0 | |
| 27 | A. Give normal saline | Yes | 1.0/1.0 | |
| 28 | D. Norepinephrine | Yes | 1.0/1.0 | |
| 29 | C. 9.0 mL/hour | Yes | 1.0/1.0 | |
| 30 | B. Hyperkalemia | Yes | 1.0/1.0 | |
| 31 | A. ↓ Na+/K+-ATPase activity → ↑ [Na+] → ↑ Ca2+ influx via Na+/Ca2+ antiporter | Yes | 1.0/1.0 | |
| 32 | D. Acute symptomatic episode of hyperthyroidism | Yes | 1.0/1.0 | |
| 33 | A. Digoxin (Lanoxin®) | Yes | 1.0/1.0 | |
| 34 | B. Metoprolol | Yes | 1.0/1.0 | |
| 35 | A. Voltage-gated sodium channels | Yes | 1.0/1.0 | |
| 36 | B. Delayed potassium channels, which open to release K+ from the cell, and L-type calcium channels, which close to block Ca2+ from entering the cell | Yes | 1.0/1.0 | |
| 37 | A. Calcium ion influx | Yes | 1.0/1.0 | |
| 38 | D. Phase 3 | Yes | 1.0/1.0 | |
| 39 | D. SA node, AV node, bundle of His, bundle branches, Purkinje fibers | Yes | 1.0/1.0 | |
| 40 | C. Increases the slope of phase 4 | Yes | 1.0/1.0 | |
| 41 | A. Atorvastatin | Yes | 1.0/1.0 | |
| 42 | B. Enalapril | No (D. Nitroglycerin) | 0.0/1.0 | |
| 43 | E. Emergent percutaneous coronary intervention | Yes | 1.0/1.0 | |
| 44 | B. Oxygen | No (D. Aspirin) | 0.0/1.0 | |
| 45 | C. Aspirin and clopidogrel | Yes | 1.0/1.0 | |
| 46 | A. Add clopidogrel for dual antiplatelet therapy | Yes | 1.0/1.0 | |
| 47 | C. It estimates bleeding risk but does not dictate anticoagulation use | Yes | 1.0/1.0 | |
| 48 | C. CHA₂DS₂-VASc score is 7; initiate oral anticoagulation | Yes | 1.0/1.0 | |
| 49 | B. Amiodarone | Yes | 1.0/1.0 | |
| 50 | C. Methadone | Yes | 1.0/1.0 |
Performance by Category
| Category | Points Earned | Points Possible | Percentage |
|---|---|---|---|
| CATEGORIES/Blooms Taxonomy/01. REMEMBER (retrieve, recall or recognize knowledge) | 2.0 | 2.0 | 100.0% |
| CATEGORIES/Blooms Taxonomy/02. UNDERSTAND (demonstration comprehension through explanation) | 8.0 | 11.0 | 72.7% |
| CATEGORIES/Blooms Taxonomy/03. APPLY (use information or skill( | 10.0 | 10.0 | 100.0% |
| CATEGORIES/Blooms Taxonomy/04. ANALYZE (classify, compare, categorize, differentiate, explain) | 22.0 | 26.0 | 84.6% |
| CATEGORIES/Blooms Taxonomy/05. EVALUATE (make judgements based on criteria or standards) | 1.0 | 1.0 | 100.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Task Categories | 43.0 | 50.0 | 86.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Task Categories/Using Diagnostic and Laboratory Studies | 1.0 | 1.0 | 100.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Task Categories/Formulating Most Likely Diagnosis | 6.0 | 7.0 | 85.7% |
| CATEGORIES/PANCE Organ Systems and Tasks/Task Categories/Managing Patients | 35.0 | 42.0 | 83.3% |
| CATEGORIES/PANCE Organ Systems and Tasks/Task Categories/Applying Basic Scientific Concepts | 11.0 | 12.0 | 91.7% |
| CATEGORIES/PANCE Organ Systems and Tasks/Task Categories/Health Maintenance, Patient Education, and | 3.0 | 3.0 | 100.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Task Categories/Clinical Intervention | 4.0 | 5.0 | 80.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Task Categories/Pharmaceutical Therapeutics | 34.0 | 40.0 | 85.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Medical Content | 43.0 | 50.0 | 86.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Medical Content/Cardiovascular System | 43.0 | 50.0 | 86.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Medical Content/Endocrine System | 3.0 | 3.0 | 100.0% |
| CATEGORIES/PANCE Organ Systems and Tasks/Medical Content/Pulmonary System | 1.0 | 1.0 | 100.0% |
| CATEGORIES/PAS 618 Medical Pharmacology II - Class of 2026 and AFTER/01. Apply basic introduction to | 7.0 | 7.0 | 100.0% |
| CATEGORIES/PAS 618 Medical Pharmacology II - Class of 2026 and AFTER/02. Identify the classes of dru | 35.0 | 42.0 | 83.3% |
| CATEGORIES/PAS 618 Medical Pharmacology II - Class of 2026 and AFTER/03. Identify classes of drugs c | 35.0 | 42.0 | 83.3% |
| CATEGORIES/PAS 618 Medical Pharmacology II - Class of 2026 and AFTER/04. Recognize the prototype and | 35.0 | 42.0 | 83.3% |
| CATEGORIES/PAS 618 Medical Pharmacology II - Class of 2026 and AFTER/13. Appraise the mechanism of a | 37.0 | 44.0 | 84.1% |
| CATEGORIES/PAS 618 Medical Pharmacology II - Class of 2026 and AFTER/17. Demonstrate skills in teamw | 1.0 | 1.0 | 100.0% |